BIOS BioPlus Acquisition Corporation

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Agreements of Certain Officers.

(b)

Executive Officers

In connection with the consummation of the Mergers and as was previously disclosed in Exhibit 99.2 to the Company’s Current Report on Form 8-K filed with the Commission on June 13, 2019, each of Stephen Deitsch and Kathryn Stalmack, each a Named Executive Officer of the Company, resigned from their positions upon the closing of the Mergers. Daniel Greenleaf, also a Named Executive Officer and the former Chief Executive Officer of the Company, resigned from his position upon the closing of the Mergers, and now serves as a special advisor to the combined company's Board of Directors (the “Board”).

As was previously disclosed in the section “The Mergers — Golden Parachute Compensation” to the Company’s definitive proxy statement on Schedule 14A, filed with the Commission on June 26, 2019, and incorporated herein by reference, each of Stephen Deitsch, Kathryn Stalmack and Daniel Greenleaf is entitled to severance in connection with their separations from employment.

Board of Directors

In connection with the Mergers, the following members of the Board resigned at the close of the Mergers: Christopher Shackelton, Daniel Greenleaf, Michael Bronfein, Michael Goldstein and Steven Neumann. No such resignation was due to a disagreement on any matter relating to the Company’s operations, policies or practices.

(c)

John Rademacher - Chief Executive Officer, President and Director of Combined Company

John Rademacher, 52 years old, will serve as the Chief Executive Officer, President and Director of the Company. A biography of Mr. Rademacher was previously disclosed in the section “The Mergers — Biographies of Option Care Designated Directors of the Combined Company” to the Company’s definitive proxy statement on Schedule 14A, filed with the Commission on June 26, 2019, and incorporated herein by reference. Mr. Rademacher was appointed to the position of Chief Executive Officer and President of the combined company on August 6, 2019.

Option Care previously entered into an employment agreement with Mr. Rademacher, which will remain in effect following the consummation of the Mergers, which is referred to herein as the “Rademacher employment agreement,” outlining his role and responsibilities and confirming the terms of his compensation arrangements. The following description of the Rademacher employment agreement is a summary of certain of its terms only and is qualified in its entirety by the full text of the Rademacher employment agreement attached hereto as Exhibit 10.1.

The Rademacher employment agreement provides for the following:

Mike Shapiro - Chief Financial Officer of Combined Company

Mike Shapiro, 49 years old, served as the Chief Financial Officer of Option Care from August 2015 until the consummation of the Mergers. Prior to joining Option Care, Mr. Shapiro was the Senior Vice President and Chief Financial Officer of Catamaran Corporation, a previously publicly-traded pharmacy benefits management company that is now part of UnitedHealth Group’s Optum Rx division, from March 2014 to July 2015 and Senior Vice President, Finance of Catamaran Corporation from February 2012 to March 2014. Mr. Shapiro was appointed to the position of Chief Financial Officer of the combined company on August 6, 2019.

Option Care previously entered into an employment agreement with Mr. Shapiro, which will remain in effect following the consummation of the Mergers, which is referred to herein as the “Shapiro employment agreement,” outlining his role and responsibilities and confirming the terms of his compensation arrangements. The following description of the Shapiro employment agreement is a summary of certain of its terms only and is qualified in its entirety by the full text of the Shapiro employment agreement attached hereto as Exhibit 10.2.

The Shapiro employment agreement provides for the following:

Harriet Booker - Chief Operating Officer of Combined Company

Harriet Booker, 53 years old, served as the Chief Operating Officer of BioScrip from November 2017 until the closing of the Mergers. Prior to that, Ms. Booker served as an executive advisor at Kate Farms, Inc., a food and beverage company, and was the Interim Senior Vice President, Revenue Cycle Management at Option Care from April 2016 until December 2016. Prior to that, Ms. Booker was the Chief Sales Officer at Coram CVS/ Specialty Infusion Services from January 2014 until April 2015. Ms. Booker was appointed to the position of Chief Operating Officer of the combined company on August 6, 2019.

Option Care previously entered into an employment agreement with Harriet Booker, which became effective following the consummation of the Mergers. A description of this employment agreement was previously disclosed in the section “The Mergers — Interests of Certain BioScrip Directors and Executive Officers in the Mergers” to the Company’s definitive proxy statement on Schedule 14A, filed with the Commission on June 26, 2019, and is incorporated herein by reference. The description of the employment agreement is a summary of certain of its terms only and is qualified in its entirety by the full text of the employment agreement attached hereto as Exhibit 10.3.

Bob Kampstra - Chief Accounting Officer of Combined Company

Bob Kampstra, 45 years old, served as the Vice President of Finance, Controller of Option Care from November 2015 until the consummation of the Mergers. Prior to that, Mr. Kampstra served as the Finance Director - Americas from September 2012 until October 2015 and Vice President - Corporate Controller from March 2006 until September 2012 at Modine Manufacturing Company, a publicly-traded thermal management company. Mr. Kampstra was appointed to the position of Chief Accounting Officer of the combined company on August 6, 2019.

(d)

Following the consummation of the Mergers and pursuant to the terms of the Merger Agreement, the Board became comprised of ten members, eight of whom were selected by Option Care (including Timothy Sullivan and Elizabeth Q. Betten of Madison Dearborn Capital Partners, LLC, the largest stockholder of Omega Parent, John J. Arlotta, Nitin Sahney and Harry M. Jansen Kraemer, Jr., three independent directors under the Nasdaq rules and Rule 10A-3 promulgated under the Exchange Act, Mark Vainisi and Alan Nielsen of Walgreen Boots Alliance, Inc., Omega Parent’s other significant stockholder, and John Rademacher, the chief executive officer of Option Care and chief executive officer of the combined company) and two of whom were appointed by BioScrip (R. Carter Pate and David W. Golding, both of whom were on the BioScrip board immediately prior to the Mergers). The Board list is as follows:

*Indicates Chairperson of Committee.